Scientists at Roche and Harvard University have discovered an entirely new class of antibiotic that can kill a highly drug-resistant ‘superbug’ with a mortality rate that can be upwards of 50% ...

The drug company has spent millions lobbying in DC. Now it's turning to the president's realty firm for help offloading a $12 ...

Roche is moving its novel antibiotic zosurabalpin into phase 3 testing for carbapenem-resistant Acinetobacter baumannii (CRAB), a 'superbug' that is considered an 'urgent threat' by the CDC, in ...

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...

Drug discovery efforts based on DNA-encoded chemical libraries are inadvertently overlooking numerous potential drug ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Two examples of FDA-approved intracameral implants are Durysta (Allergan) and iDoseTR (Glaukos), both of which provide ...

Recursion Pharmaceuticals is transforming drug discovery with AI-driven RecursionOS, slashing costs and boosting development ...

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to ...